Napon-Zongo D, Diendere J, Sanou A, Coulibaly A, Dera A, Ouattara N
JGH Open. 2024; 8(12):e70069.
PMID: 39655240
PMC: 11626251.
DOI: 10.1002/jgh3.70069.
Wen H, Deng H, Yang L, Li L, Lin J, Zheng P
Cochrane Database Syst Rev. 2024; 10:CD015033.
PMID: 39412049
PMC: 11481097.
DOI: 10.1002/14651858.CD015033.pub2.
Katsarou A, Tsioulos G, Kassi E, Chatzigeorgiou A
Hormones (Athens). 2024; 23(4):621-636.
PMID: 39112786
DOI: 10.1007/s42000-024-00588-1.
El-Baz A, Shata A, Nouh N, Jamil L, Hafez M, Negm S
AMB Express. 2024; 14(1):89.
PMID: 39095672
PMC: 11297008.
DOI: 10.1186/s13568-024-01731-2.
Abdelkhalik M, Al Tawil S, El Fouani A, Allakiss N, Mattar L, Faour W
PLoS One. 2024; 19(8):e0306825.
PMID: 39093889
PMC: 11296626.
DOI: 10.1371/journal.pone.0306825.
Misoprostol for non-alcoholic steatohepatitis: a randomised control trial.
Siyal M, Abbas Z, Qadeer M, Saeed A, Ali U, Khatoon A
BMJ Open Gastroenterol. 2024; 11(1).
PMID: 38844374
PMC: 11167449.
DOI: 10.1136/bmjgast-2023-001342.
Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes.
Alexopoulos A, Parish A, Olsen M, Batch B, Moylan C, Crowley M
Endocr Pract. 2024; 30(7):663-669.
PMID: 38697305
PMC: 11223982.
DOI: 10.1016/j.eprac.2024.04.018.
Awareness of Non-alcoholic Fatty Liver Disease and Its Determinants in Jazan, Saudi Arabia: A Cross-Sectional Study.
Abdulfattah A, Elmakki E, Maashi B, Alfaifi B, Almalki A, Al Alhadi N
Cureus. 2024; 16(1):e53111.
PMID: 38414702
PMC: 10897741.
DOI: 10.7759/cureus.53111.
Electronic sanitary database: a new potential tool to identify occult chronic liver disease in general population.
Cagnin S, Martini A, Donato D, Angeli P, Pontisso P
Intern Emerg Med. 2024; 19(3):641-647.
PMID: 38227274
PMC: 11039494.
DOI: 10.1007/s11739-023-03507-1.
Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions.
Wazir H, Abid M, Essani B, Saeed H, Khan M, Nasrullah F
Cureus. 2024; 15(12):e49920.
PMID: 38174191
PMC: 10763979.
DOI: 10.7759/cureus.49920.
How non-alcoholic fatty liver disease and cirrhosis affect the heart.
Moller S, Wiese S, Barlose M, Hove J
Hepatol Int. 2023; 17(6):1333-1349.
PMID: 37770804
DOI: 10.1007/s12072-023-10590-1.
Development and validation of a non-invasive model for predicting significant fibrosis based on patients with nonalcoholic fatty liver disease in the United States.
Guo Y, Shen B, Xue Y, Li Y
Front Endocrinol (Lausanne). 2023; 14:1207365.
PMID: 37732127
PMC: 10507901.
DOI: 10.3389/fendo.2023.1207365.
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.
Lukkunaprasit T, Tansawet A, Boonmanunt S, Sobhonslidsuk A, Mckay G, Attia J
Sci Rep. 2023; 13(1):5824.
PMID: 37037891
PMC: 10086025.
DOI: 10.1038/s41598-023-33023-3.
Recent Research and Insights on the Disease Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Younossi Z
Gastroenterol Hepatol (N Y). 2023; 19(2):108-110.
PMID: 36866111
PMC: 9972607.
Adipose-targeted SWELL1 deletion exacerbates obesity- and age-related nonalcoholic fatty liver disease.
Gunasekar S, Heebink J, Carpenter D, Kumar A, Xie L, Zhang H
JCI Insight. 2023; 8(5).
PMID: 36749637
PMC: 10077479.
DOI: 10.1172/jci.insight.154940.
Alleviation Effects of Microbial Metabolites from Resveratrol on Non-Alcoholic Fatty Liver Disease.
Guo J, Wang P, Cui Y, Hu X, Chen F, Ma C
Foods. 2023; 12(1).
PMID: 36613310
PMC: 9818778.
DOI: 10.3390/foods12010094.
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease.
Josloff K, Beiriger J, Khan A, Gawel R, Kirby R, Kendrick A
J Cardiovasc Dev Dis. 2022; 9(12).
PMID: 36547416
PMC: 9786069.
DOI: 10.3390/jcdd9120419.
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis.
Shi Y, Fan J
Clin Mol Hepatol. 2022; 29(Suppl):S228-S243.
PMID: 36521452
PMC: 10029951.
DOI: 10.3350/cmh.2022.0401.
The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease.
Gao N, Deng J, Wang J, Zhou Z, Yao C, Zhou M
Front Med (Lausanne). 2022; 9:1038475.
PMID: 36457563
PMC: 9705575.
DOI: 10.3389/fmed.2022.1038475.
A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies.
Lefever D, Miedel M, Pei F, DiStefano J, DeBiasio R, Shun T
Metabolites. 2022; 12(6).
PMID: 35736460
PMC: 9227696.
DOI: 10.3390/metabo12060528.